ROBO1 and hepatocellular carcinoma: Our findings suggested that ROBO1 was positively correlated with five immune checkpoint molecules, PDCD1, CTLA4, TIGIT, BTN2A1 and BTN2A, in HCC, reflecting that ROBO1 inhibitors may have a synergistic effect and enhance the potency of ICBs to improve therapeutic efficiency in HCC patients.